Amendments to the Claims:

1-3. (Canceled).

4. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a safe and effective amount of the compound of formula I or the pharmaceutically acceptable salts thereof, wherein



Formula (I)

R_1 is methyl, ethyl or trifluoromethyl at position 3, 4, 5 or 6;

R_2 is hydroxyl, sulfydryl, methylthio group, or ethylthio group at position 2, 3 or 4.

5. (Currently amended) The pharmaceutical composition according to claim ~~3~~ 4 comprising 0.01-99% of the compound of formula I or the pharmaceutically acceptable salts thereof, on the basis of the total weight.

6. (Currently amended) A pharmaceutical composition according to claim ~~3~~ 4, wherein the dosage form of the pharmaceutical composition is tablet, capsule, ampule or pill.

7. (Withdrawn) A method for producing the compound of formula I, comprising the steps of:

(a) in the presence of copper powder and anhydrous alkaline earth metal carbonate, reacting the compound of formula II and the compound of formula III at 160-200° C., thereby producing the compound of formula Ia;



wherein

R_1 is methyl, ethyl or trifluoromethyl at position 3, 4, 5 or 6,

R_3 is --OCH_3, --SCH_3, --OC_2H_5 or --SC_2H_5 at position 2, 3 or 4, and

X is Cl, Br or I;

(b) reacting the compound of formula Ia and BBr_3 in an inert solvent at -10° C. to 15° C., thereby producing the compound of formula I:



wherein, R_1 and R_3 are defined as above, and R_2 is -OH or -SH.

8. (Withdrawn) A method for producing a pharmaceutical composition, comprising the steps of mixing the compound of formula I or the pharmaceutically acceptable salts thereof according to claim 1 with a pharmaceutically acceptable carrier to produce a pharmaceutical composition comprising 0.01-99 wt % of the compound of formula I, on the basis of the total weight.

9. (Withdrawn) Use of the compound of formula I or the pharmaceutically acceptable salts thereof according to claim 1 in the manufacture of a medicament for preventing fibrosis.

10. (Withdrawn) A method for treating fibrosis diseases, comprising administrating a safe and effective amount of the compound of formula I or the pharmaceutically acceptable salts thereof according to claim 1 to a subject in need thereof.

11. (New) The pharmaceutical composition according to claim 4, wherein R_1 is methyl, and R_2 is hydroxyl

12. (New) The pharmaceutical composition according to claim 4, wherein R_1 is methyl at position 5, and R_2 is hydroxyl at position 4.

13. (New) The pharmaceutical composition according to claim 4 further comprises one or more pharmaceutically acceptable carriers or excipients.

14. (New) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is administered orally, intravenously, intramuscularly or subcutaneously.

15. (New) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is orally administered.

16. (New) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is administered by external use.

17. (New) The pharmaceutical composition according to claim 15, wherein the dosage form of the pharmaceutical composition is ointment, gel, or drug-containing rubber cement.

18. (New) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is administered parenterally.

19. (New) The pharmaceutical composition according to claim 4 comprising 0.1-90% of the compound of formula I or the pharmaceutically acceptable salts thereof, on the basis of the total weight.

20. (New) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is administered at a dose of about 0.25-1000 mg/kg animal body weight per day.

21. (New) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is administered at a dose of about 2-80 mg/kg animal body weight per day.

22. (New) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is administered in 2-4 separated dosages per day, or in the form of slow release.

23. (New) The pharmaceutical composition according to claim 13, wherein said carrier comprises a solid carrier selected from the group consisting of starch, lactin, dicalcium phosphate, microcrystalline cellulose, sucrose and white bole.

24. (New) The pharmaceutical composition according to claim 13, wherein said carrier comprises a liquid carrier selected from the group consisting of sterile water, polyethylene glycol, nonionic surfactant and edible oil.

25. (New) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition comprises an adjuvant selected from the group consisting of a flavoring agent, colorant, preservative and antioxidant such as vitamin E, vitamin C, BHT and BHA.